Table 2. Endostatin genotype distributions in osteosarcoma patients stratified by clinical and laboratory variables.
| Patients number | Wild+p.104DN(%) | p.104NN(%) | p-value | |
|---|---|---|---|---|
| Sex | 1.00 | |||
| Male | 139 | 134(96.4) | 5(3.6) | |
| Female | 97 | 94(96.9) | 3(3.1) | |
| Age | 1.00 | |||
| 20≤ | 162 | 157(96.9) | 5(3.1) | |
| >20 | 74 | 71(95.9) | 3(4.1) | |
| Histologic subtype | 0.65 | |||
| Osteoblastic | 146 | 142(97.3) | 4(2.7) | |
| Chondroblastic | 35 | 33(94.3) | 2(5.7) | |
| Fibroblastic | 21 | 20(95.2) | 1(4.8) | |
| Other | 34 | 33(97.1) | 1(2.9) | |
| Grade | 1.00 | |||
| III | 61 | 59(96.7) | 2(3.3) | |
| IV | 175 | 169(96.6) | 6(3.4) | |
| Enneking stage | 0.72 | |||
| 2A | 59 | 56(94.9) | 3(5.1) | |
| 2B | 177 | 172(97.2) | 5(2.8) |
Wild, no polymorphism; p.104DN, heterozygous polymorphism; p.104NN, homozygous polymorphism.